ArticleChinese medicine2025
Detumescence Analgesic Plaster mitigates knee osteoarthritis via active ingredients targeting mitochondrial complex 1/AMPK/MYL3-regulated cartilage homeostasis.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe Detumescence Analgesic Plaster (DAP) has been widely used in clinical practice for knee osteoarthritis (KOA) treatment, yet its active ingredients and molecular mechanisms remain incompletely understood. PURPOSE: This study aimed to systematically characterize DAP's chemical composition and decipher its chondroprotective pathways in KOA.
methodsA papain-induced KOA rat model was employed to evaluate DAP's therapeutic effects through behavioral assessments (mechanical withdrawal threshold, gait analysis) and histological evaluations (H&E, safranin O-fast green staining). UPLC-Q-TOF/MS combined with Franz diffusion cells identified DAP's chemical profile. RNA-seq was performed to compare gene expression between KOA and DAP-treated groups, followed by protein-protein interaction (PPI) and gene co-expression network analysis to prioritize key targets. Validation was conducted using Western blot, qPCR, and immunohistochemistry. IL-1β-stimulated chondrocytes were used to screen active ingredients and validate their effects on mitochondrial function.
resultsDAP treatment significantly alleviated pain, restored joint mobility, and preserved cartilage integrity in KOA rats. Chemical profiling identified 92 compounds, including 28 active ingredients with high transdermal permeability. RNA-seq revealed 206 DAP-reversed genes primarily associated with mitochondrial dysfunction, oxidative stress, and inflammatory signaling. Network analysis pinpointed 23 core targets, with mitochondrial complex I subunits (NDUFA5, NDUFA6, NDUFS6), AMPK, and MYL3 emerging as critical nodes in oxidative phosphorylation. DAP restored the expression of these targets in KOA cartilage. In vitro experiments demonstrated that 1,5-dicaffeoylquinic acid, verproside, and catalposide attenuated ROS production, enhanced ATP synthesis, and stabilized mitochondrial membrane potential via the NDUFA6/AMPK/MYL3 axis, thereby inhibiting chondrocyte apoptosis.
conclusionThis study provides the first evidence that DAP exerts chondroprotective effects by ameliorating mitochondrial dysfunction and oxidative stress in KOA through the mitochondrial complex I/AMPK/MYL3 signaling pathway. These findings offer a mechanistic basis for DAP's clinical efficacy and highlight potential therapeutic targets for KOA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.